LIDEX-E
LOE ApproachingNDATOPICALCREAM
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX-E is a topical cream formulation approved in 1971 as a small-molecule NDA. The generic composition and therapeutic indications are not publicly specified in available data. Typical topical creams of this era are used for dermatological conditions.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating defensive positioning and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LIDEX-E represents a mature product role focused on defending market position and managing lifecycle transition. Career growth is limited; this role suits professionals seeking stability in a consolidation phase rather than launch momentum.
Brand ManagerField Sales Representative
Worked on LIDEX-E at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.